Mabwell (Shanghai) Bioscience Co Ltd Class A 688062
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
-
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
-
Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's NMPA
-
FDA Grants Orphan Drug Designation to 7MW3711
-
Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC
-
FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Locally Advanced or Metastatic Nectin-4 Positive TNBC
Trading Information
- Previous Close Price
- ¥22.05
- Day Range
- ¥22.08–24.16
- 52-Week Range
- ¥19.90–37.00
- Bid/Ask
- ¥24.00 / ¥24.01
- Market Cap
- ¥9.59 Bil
- Volume/Avg
- 2.8 Mil / 3.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 57.31
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,402
- Website
- https://www.mabwell.com
Comparables
Valuation
|
Metric
|
688062
|
300122
|
301207
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 9.77 | 14.58 |
Price/Book Value | 4.06 | 1.84 | 1.72 |
Price/Sales | 57.31 | 1.24 | 4.43 |
Price/Cash Flow | — | 8.06 | 10.76 |
Price/Earnings
688062
300122
301207
Financial Strength
|
Metric
|
688062
|
300122
|
301207
|
|---|---|---|---|
Quick Ratio | 1.53 | 1.37 | 2.85 |
Current Ratio | 1.78 | 2.07 | 3.42 |
Interest Coverage | −32.55 | 76.85 | 149.96 |
Quick Ratio
688062
300122
301207
Profitability
|
Metric
|
688062
|
300122
|
301207
|
|---|---|---|---|
Return on Assets (Normalized) | −24.26% | 11.64% | 9.24% |
Return on Equity (Normalized) | −41.90% | 19.62% | 11.52% |
Return on Invested Capital (Normalized) | −26.98% | 17.67% | 10.82% |
Return on Assets
688062
300122
301207
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zlbytxndpb | Fzc | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gbnmsyrvb | Wsvgkk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cpgbcjdph | Jzdkzr | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hqqwypwr | Mqlddd | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Wlytyvt | Xdfz | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nmzmkdcb | Kyw | $28.0 Bil | |||
| Moderna Inc
MRNA
| Gjhqnwkft | Gkbz | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Tzrbfwny | Flx | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mwbyjvssz | Hhdrw | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gztwxpnbz | Tfhqzh | $12.6 Bil |
United States